Recombinant CD319: Enhance Your Research with Quality Solutions

Recombinant CD319, developed by Alpha Lifetech Incorporation, is a cutting-edge Protein designed for advanced research in immunology and cancer therapy. As a vital component in studies of immune response, CD319, also known as SLAMF7, plays a critical role in the regulation of immune cells, particularly in the context of multiple myeloma and other hematological malignancies, This high-quality recombinant protein is produced using state-of-the-art techniques to ensure maximum purity and bioactivity, making it ideal for applications such as functional assays, protein interaction studies, and therapeutic development. Researchers can leverage this product to explore CD319's potential as a biomarker and therapeutic target, paving the way for innovative treatments and deeper understanding of immune system dynamics, Alpha Lifetech Incorporation is committed to providing exceptional products that drive scientific discovery. Experience the advantages of recombinant CD319 and elevate your research to new heights with our reliable and precise solutions

Hot Selling Product

ALP64505-Recombinant Human CD24 Protein, mFc Tag

ALP64562-Recombinant Rhesus Macaque CD160 Protein, Fc Tag

ALP64506-Recombinant Human Biotinylated CD28 Protein, Fc Tag, Avi Tag

ALP64513-Recombinant Human TNFRSF17/BCMA Protein, His Tag, Flag Tag

ALP64514-Recombinant Human 5T4/TPBG Protein, Avi Tag, His Tag

ALP64515-Recombinant Human CD73 Protein, Fc Tag

Top Picks For recombinant CD319 Industry Leaders Pioneers in the Field

In the rapidly evolving landscape of the recombinant CD319 industry, leaders are emerging who are not only advancing science but also enhancing the capabilities of research facilities worldwide. Alpha Lifetech Inc., founded by experienced scientists in membrane protein production, Nanobody discovery, and monoclonal development, stands out as a pioneer in this field. With a remarkable portfolio that includes nearly 10,000 high-quality spot membrane protein reagents, cytokines, and drug target antibodies, Alpha Lifetech is committed to driving innovation and supporting global researchers. As the demand for effective and reliable biotechnology solutions continues to rise, procurement professionals in the life sciences sector are increasingly seeking out established suppliers that can meet their specific needs. Alpha Lifetech offers an extensive range of products that not only comply with stringent quality standards but also empower scientists to achieve breakthroughs in their research. By prioritizing quality and offering a wealth of scientific expertise, Alpha Lifetech has positioned itself as a trusted partner for organizations across the globe. For those looking to make informed decisions in sourcing recombinant CD319 products, collaborating with a leader like Alpha Lifetech Inc. ensures access to cutting-edge reagents and exceptional support. As the industry progresses, aligning with innovators who share a vision of advancing health and science is more crucial than ever for procurement professionals. Choose Alpha Lifetech Inc. for reliable, high-quality solutions that enable scientific success in the recombinant CD319 landscape.

Top Picks For Recombinant CD319 Industry Leaders Pioneers in the Field

Company Type	Market Focus	R&D Investment (Million USD)	Years Established	Key Innovations
Biotechnology	Immunotherapy	150	10	CD319 Antibody Development
Pharmaceutical	Cancer Treatment	200	8	Next-Gen CAR-T Therapies
Research Institute	Cellular Biology	120	15	Innovative Cell Line Development
Diagnostics	Biomarker Discovery	80	12	Novel Biomarker Identification
Venture Capital	Investment in Biotech	300	5	Funding for Innovative Therapies

How To Select recombinant CD319 Ahead of the Curve Trusted by Pros

The recombinant CD319 industry has witnessed a steady increase in research output over recent years, as depicted in the line chart above. Starting from 150 publications in 2018, the number of research articles has shown a remarkable uptrend, reaching approximately 800 by 2023. This growth can be attributed to numerous factors, including advancements in biotechnological methods and increasing investments in immunotherapy and cell therapy research. The spike in 2022 suggests that the scientific community is increasingly recognizing the significance of CD319 in potential therapeutic applications, particularly in treating various cancers and autoimmune diseases. The trend indicates a promising future for the recombinant CD319 field, signaling opportunities for innovation and collaboration among researchers and practitioners. Ongoing studies and trials are anticipated to further enhance our understanding and foster developments that could benefit patients worldwide, especially in precision medicine approaches. The rising publication trend reflects both the growing interest and the groundbreaking advancements being made in this vital area of biomedical research.